Physician profile
Karol Watson
NPI 1184646358
$552,565.93
in general payments reported to CMS, 2019-2025
19 companies · $23K in 2025
The $23K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106K · 2020: $153K · 2021: $124K · 2022: $70K · 2023: $37K · 2024: $40K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $73K · Consulting Fee: $16K · Travel and Lodging: $7,871 · Food and Beverage: $2,763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $72,800.00 |
| Consulting Fee | $16,275.00 |
| Travel and Lodging | $7,870.62 |
| Food and Beverage | $2,763.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $287,155.06 | 2019-2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195,594.73 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $20,047.38 | 2020-2024 | Leqvio |
| Amgen INC. | $17,043.19 | 2019-2023 | Repatha |
| Merck Sharp & Dohme LLC | $9,483.21 | 2021-2025 | Verquvo |
| Eli Lilly and Company | $6,275.00 | 2021-2022 | |
| Novo Nordisk INC | $5,749.63 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $2,945.00 | 2020 | |
| Mallinckrodt Enterprises LLC | $2,700.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $2,148.00 | 2022 | |
| Csl Behring | $1,560.00 | 2020 | |
| Urovant Sciences INC | $1,000.00 | 2022 | |
| Shockwave Medical, INC | $222.76 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $143.85 | 2025 | Evkeeza |
| Philips North America LLC | $137.34 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $134.69 | 2023 | Pk Papyrus, Orsiro Mission |
| Corcept Therapeutics | $127.24 | 2024 | Korlym |
| Kestra Medical Technology Services, INC. | $96.36 | 2023 | Assure Wcd |
| Travere Therapeutics, INC. | $2.49 | 2020-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karol Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.